Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Phase 2 Completed
68 enrolled 13 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
MK-3543-005
Phase 2 Completed
81 enrolled 13 charts
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Phase 2 Completed
4 enrolled 10 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Phase 2 Completed
31 enrolled 8 charts
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 2 Completed
61 enrolled 10 charts
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Phase 2 Completed
6 enrolled 11 charts
AIRPORT-MPN
Phase 2 Completed
44 enrolled
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
Phase 2 Completed
56 enrolled 9 charts
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Phase 2 Completed
95 enrolled 32 charts
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Phase 2 Completed
50 enrolled 11 charts
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Phase 2 Completed
39 enrolled 13 charts
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Phase 2 Completed
23 enrolled 31 charts
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Phase 2 Completed
125 enrolled 38 charts
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Phase 2 Completed
80 enrolled 31 charts
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Phase 2 Completed
10 enrolled 7 charts
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
140 enrolled
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase 2 Completed
213 enrolled 19 charts
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Phase 2 Completed
54 enrolled 16 charts
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 2 Completed
77 enrolled 16 charts
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Phase 2 Completed
29 enrolled 8 charts
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Phase 2 Completed
88 enrolled 22 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
ALBUM
Phase 2 Completed
16 enrolled 7 charts
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Phase 2 Completed
25 enrolled 8 charts
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Phase 2 Completed
16 enrolled 10 charts
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Phase 2 Completed
142 enrolled 11 charts
An Open-label Phase II Study of Lorvotuzumab Mertansine
Phase 2 Completed
9 enrolled 7 charts
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Phase 2 Completed
21 enrolled 13 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Phase 2 Completed
49 enrolled 4 charts
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Phase 2 Completed
18 enrolled
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Phase 2 Completed
34 enrolled
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2 Completed
185 enrolled
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Phase 2 Completed
455 enrolled
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Phase 2 Completed
17 enrolled 9 charts
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 10 charts
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Phase 2 Completed
57 enrolled
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Phase 2 Completed
26 enrolled 13 charts
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase 2 Completed
35 enrolled 8 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase 2 Completed
32 enrolled 24 charts
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Phase 2 Completed
48 enrolled 7 charts
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Phase 2 Completed
41 enrolled 15 charts